Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports

被引：0

作者：

Joost J. Enzing

Saskia Knies

Jop Engel

Maarten J. IJzerman

Beate Sander

Rick Vreman

Bert Boer

Werner B. F. Brouwer

机构：

[1] Erasmus University Rotterdam,Erasmus School of Health Policy & Management

[2] Zorginstituut Nederland,Cancer Health Services Research, School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences

[3] University of Melbourne,Health Technology and Services Research Department, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre

[4] University of Twente,Toronto Health Economics and Technology Assessment (THETA) Collaborative

[5] University Health Network,Institute of Health Policy, Management and Evaluation (IHPME)

[6] University of Toronto,Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences

[7] Public Health Ontario,undefined

[8] ICES,undefined

[9] Utrecht University,undefined

来源：

Cost Effectiveness and Resource Allocation | / 20卷

关键词：

Health Technology Assessment; HTA; HTA agencies; Reimbursement decision making; Profitability; Profit margin; Drug pricing; Pharmaceuticals; Pricing models;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 34 条

[1] Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports
Enzing, Joost J.
Knies, Saskia
Engel, Jop
IJzerman, Maarten J.
Sander, Beate
Vreman, Rick
Boer, Bert
Brouwer, Werner B. F.
[J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
[2] HEALTH TECHNOLOGY ASSESSMENT, PRICE AND REIMBURSEMENT REVIEW FOR ORPHAN DRUGS IN ITALY
Tavella, F.
Korchagina, D.
Rodrigues, J.
Remuzat, C.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A540 - A540
[3] Use of health technology assessment in drug reimbursement decisions in China
Chen, Wen
Zhang, Luying
Hu, Min
Hu, Shanlian
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 381
[4] APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHINA NATIONAL REIMBURSEMENT DRUG LIST PRICE NEGOTIATIONS: THE EVOLVING TREND AND IMPLICATIONS
Li, H. J.
Sun, R.
Liu, J.
Ming, J.
Zhao, X.
Liu, Y.
Xie, Y.
[J]. VALUE IN HEALTH, 2020, 23 : S139 - S139
[5] Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study
Nicod, Elena
Maynou, Laia
Visintin, Erica
Cairns, John
[J]. HEALTH ECONOMICS POLICY AND LAW, 2020, 15 (03) : 386 - 402
[6] Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden
Pettersson, Billie
Hoffmann, Mikael
Wandell, Per
Levin, Lars-Ake
[J]. HEALTH POLICY, 2012, 104 (01) : 84 - 91
[7] Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden
Pettersson, Billie
Hoffmann, Mikael
Andersson, David
Wandell, Per
Levin, Lars-Ake
[J]. HEALTH POLICY, 2012, 108 (2-3) : 207 - 215
[8] Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland
Gorry, Claire
Daly, Maria
Barrett, Rosealeen
Finnigan, Karen
Smith, Amelia
Doran, Stephen
Duggan, Bernard
Clarke, Sarah
Barry, Michael
[J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024,
[9] Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement
Wang, Ting
McAuslane, Neil
Goettsch, Wim G.
Leufkens, Hubert G. M.
De Bruin, Marie L.
[J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
[10] IS NATIONAL HEALTH TECHNOLOGY ASSESSMENT AN OPTIMAL MODEL FOR MEDICAL DEVICE REIMBURSEMENT? CASE STUDY: FRANCE
Macaulay, R.
Magimaidas, A.
Nguyen, H.
Hugon, M.
[J]. VALUE IN HEALTH, 2019, 22 : S221 - S221

← 1 2 3 4 →